AstraZeneca says FDA approves Imfinzi-BCG combo for high-risk non-muscle-invasive bladder cancer

AstraZeneca PLC

AstraZeneca PLC

AZN

0.00
  • AstraZeneca secured US FDA clearance for Imfinzi with BCG to treat BCG-naïve, high-risk non-muscle-invasive bladder cancer.
  • POTOMAC Phase III data showed a 32% cut in recurrence, progression, or death risk at one year versus BCG alone.
  • Regulatory reviews are ongoing in the EU, Japan, and other markets.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202605282118BIZWIRE_USPR_____20260528_BW610886) on May 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.